A trial comparing ofatumumab and duvelisib for leukaemia or lymphoma that has continued to grow despite treatment (DUO)
Cancer type:
Status:
Phase:
This trial compared ofatumumab and duvelisib for chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It was for people with CLL or SLL that had come back or continued to grow despite having other treatment.
The trial was open for people to join in 2014 and 2015. The research team published the results in 2018.
More about this trial
Chronic lymphocytic leukaemia (CLL) is a cancer of white blood cells called lymphocytes. If the cancerous lymphocytes are in the lymph nodes rather than in the blood, doctors may call it small lymphocytic lymphoma (SLL). The treatments for CLL and SLL are the same.
Ofatumumab is a type of targeted treatment called a monoclonal antibody. It can seek out cancer cells by looking for particular proteins. When this trial was done, doctors often used ofatumumab to treat CLL or SLL that had come back after treatment.
Duvelisib is another type of targeted treatment called a cancer growth blocker. It stops signals that cancer cells use to divide and grow.
Doctors wanted to find out how well duvelisib works for people with CLL or SLL that had come back after treatment.
The people taking part in this trial were put into 1 of 2 treatment groups at random:
- half had ofatumumab
- half had duvelisib
The main aims of the trial were to find out:
- how well duvelisib and ofatumumab work
- more about the side effects
Summary of results
As part of our editorial policy, any trial information we write is checked externally before we put it on our website. The research team have published some results for this trial. But we have been unable to find anyone involved with the trial to check the summary for us.
This means we are not able to include a plain English summary of the results on this page.
More information
There is more information about this trial in the link to the medical journal below.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W. Flinn and others
Blood, 2018. Volume 132, issue 23, pages 2446 – 2455.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Peter Hillmen
Supported by
Infinity Pharmaceuticals, Inc
NIHR Clinical Research Network: Cancer
Verastem Oncology
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
